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alytic technique has increased rapidly. A piggyback study
is performed alongside an existing clinical trial, leaving the
clinical components intact and undisturbed. Because clini-
cal safety and efficacy are the drivers behind the trial, ef-
forts are made to ensure that clinical endpoints are not
compromised by the economic substudy. This growing em-
phasis on cost-effectiveness and improvements in humanis-
tic attributes (QOL, ADLs, functioning) has caused many
researchers to add poor economic and quality of life sub-
studies in an attempt to tell compelling stories about their
products. PE/QOL studies should be developed with a
strong foundation. This workshop will provide a detailed
review of the fundamental steps necessary to properly de-
sign a piggyback study in the international setting. These
steps are: the development of a priori objectives and target
audience; hypotheses; endpoints to be measured; definition
of the target population; selection of appropriate compara-
tors; the time-frame to be analyzed; determination of how
the data shall be collected; creation of an analysis plan;
costing the data; data analysis; and, lastly, the reporting of
the results in a concise and meaningful way. Defining the
objectives and hypotheses will be the focus of the work-
shop, with a review of the other steps. This session is di-
rected at individuals in pharmaceutical firms, contract re-
search organizations (CROs), and consultant companies
who are responsible for the design and conduct of pharma-
coeconomic evaluations.
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This workshop offers a critical examination of the use of
patient self-reports in pharmacoeconomic evaluations. It is
directed at individuals in pharmaceutical firms, CROs, and
consultant companies who are responsible for the design
and conduct of pharmacoeconomic evaluations. This work-
shop advances current research by concentrating on how
the data collection method—in prospective clinical eco-
nomic evaluations—influences study results. Scant atten-
tion has been paid to the fact that the high level of internal
validity found in prospective studies may be compromised
by the application of inappropriate methodologies to data
collection. Particular attention in this workshop is placed
on how validity may be affected by the elapsed time be-
tween admission and reporting, the salience of the treat-
ment event and the perceived social desirability of the
condition. As part of this workshop, we will demonstrate
specific areas where estimates based on patient self-reports
lead to either reliable or suspect values. In particular, we
examine areas of hospitalization, outpatient consultations,
medication use and indirect costs. The impact of patient
self-reports on cost-effectiveness ratios is also discussed.
Attendees of this workshop will gain an understanding of
current methodological shortcomings in this area. Re-
searchers and readers of pharmacoeconomic studies will
gain the skills necessary to better design and evaluate the
validity and potential bias in cost effectiveness analyses.
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In pharmacoeconomics, the comparison of costs generated
by the use of two different drugs for the same treatment is
of great interest. The problem is especially challenging
when the drugs are likely to produce costly adverse effects
in a small number of patients. The distribution of cost data
is likely to be skewed, and therefore traditional statistical
methods may be inappropriate to analyze the difference in
mean costs. The objective of this workshop is to discuss
the limitations of classical statistical methods used for cost
analysis, and to present an alternative method appropriate
to deal with skewed data. In this workshop, a pharmaco-
economic cost analysis example with skewed data will be
presented. The bootstrap method will be presented as an
alternative approach. Cost analysis will be demonstrated
on an example with classical and alternative methods. The
following statistical methods and their limitations will be
discussed: 1) the Student’s t test, which assumes normality
of data and is sensitive to data skewed for small to moder-
ate sample sizes; 2) the t test on log-transformed data,
which assumes log-normal distributions and equality of
variances of log-transformed data for both samples; and 3)
the nonparametric rank tests, which assumes that the dis-
tributions of data have the same shape and variance. The
bootstrap method will be shown to produce the most reli-
able results for the example given. The use of the nonpara-
metric bootstrap test for most pharmacoeconomic cost
analyses with skewed data and with small to moderate
sample sizes will be discussed. No restricting assumptions
are needed for its application and its ability to deal with
skewing makes it an appropriate alternative.
